Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis

[1]  J. Silverberg,et al.  Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis , 2020, JAMA dermatology.

[2]  J. Bauman,et al.  P190 - The effect of CYP2C9 and CYP2C19 genotype on the pharmacokinetics of PF 04965842, A JAK1 inhibitor in clinical development , 2020 .

[3]  A. Nader,et al.  Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials , 2019, Journal of clinical pharmacology.

[4]  E. Peeva,et al.  Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis , 2019, JAMA dermatology.

[5]  S. Tarabar,et al.  Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study , 2018, British journal of clinical pharmacology.

[6]  Z. Draelos,et al.  Efficacy and safety of the Janus kinase 1 inhibitor PF‐04965842 in patients with moderate‐to‐severe psoriasis: phase II, randomized, double‐blind, placebo‐controlled study , 2018, The British journal of dermatology.

[7]  B. Strober,et al.  Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis , 2018, Clinical pharmacology in drug development.

[8]  Mark J. Mitton-Fry,et al.  Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. , 2018, Journal of medicinal chemistry.

[9]  A. Othman,et al.  Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials , 2017, Clinical Pharmacokinetics.

[10]  C. Knibbe,et al.  Hepatic Drug Metabolism in Pediatric Patients , 2017 .

[11]  K. Ueda,et al.  Pharmacokinetics and Differential Regulation of Cytochrome P450 Enzymes in Type 1 Allergic Mice , 2016, Drug Metabolism and Disposition.

[12]  D. Tibboel,et al.  Drug metabolism for the paediatrician , 2014, Archives of Disease in Childhood.

[13]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[14]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods , 2013, CPT: pharmacometrics & systems pharmacology.

[15]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development , 2012, CPT: pharmacometrics & systems pharmacology.

[16]  Jonathan L. Kaye,et al.  Review of paediatric gastrointestinal physiology data relevant to oral drug delivery , 2011, International Journal of Clinical Pharmacy.

[17]  ET Morgan,et al.  Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics , 2009, Clinical pharmacology and therapeutics.

[18]  Julie A. Johnson,et al.  Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms , 2004, Journal of clinical pharmacology.

[19]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.